Stay updated with breaking news from John Berdahl. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Glaukos Corporation , an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today...
An intracameral implant that releases travoprost into the eye over an extended period to lower intraocular pressure in glaucoma and ocular hypertension will be available commercially in early 2024.
Revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease severity iDose TR was designed to usher in a new era of interventional glaucoma by enabling a proactive...
14.12.2023 - Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, announced today the U.S. Food and Drug Administration ... Seite 1
A single travoprost implant proved noninferior to timolol eye drops, with good safety